Cern Corp, Inc. Delaware “C” formed to develop/ commercialize an effective, non-drug (drug/photosensitizer optional) therapeutic treatment for fungal and bacterial vaginosis using low-level microbicidal light administered as a small insertable device with a consumable gel/phtosensitizer. USPTO Patents now granted both Utility and Design and Int'l as well as Trademark. FDA Class 2 DeNovo 510K as a Class II.
Human clinicals over 60 Treated